Every 10-Q that TruBridge Inc (TBRG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TBRG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TBRG filings page.
TruBridge, Inc. reported Q3 2025 results, showing steady revenue and a swing to profitability. Total revenue was $86,106 thousand versus $84,700 thousand a year ago, with segment revenue of $54,501 thousand from Financial Health and $31,605 thousand from Patient Care. Operating income rose to $4,068 thousand from $2,814 thousand. Net income was $5,602 thousand compared with a net loss of $9,148 thousand in Q3 2024, or $0.37 per diluted share.
For the nine months, revenue reached $259,043 thousand versus $254,416 thousand, and net income was $8,641 thousand versus a net loss of $15,390 thousand. Interest expense declined year over year, and the company recorded an income tax benefit influenced by the July 2025 OBBBA legislation allowing deductibility of domestic R&D. Cash from operations was $28,107 thousand year-to-date, ending cash was $19,920 thousand, and total debt obligations were $165,166 thousand, with long‑term debt of $161,363 thousand. Deferred revenue ended at $8,197 thousand. As of November 4, 2025, shares outstanding were 15,008,986.
TruBridge reported a quarter of positive operating results and improved profitability. Total revenues were $85.7 million for the three months ended June 30, 2025, essentially flat with the prior year period, while the company recorded GAAP net income of $2.58 million for the quarter and $3.04 million for the six months ended June 30, 2025, reversing prior-year losses. Adjusted EBITDA rose to $31.97 million for the six-month period from $23.77 million a year earlier, driven by expense reductions and higher recurring revenue.
The balance sheet shows $12.28 million in cash, total assets of $390.15 million and long-term debt (less current portion) of $163.11 million. Credit losses and financing receivables trends warrant attention: the allowance for credit losses increased to $0.82 million and total financing receivables declined to $2.75 million. The Patient Care reporting unit carries an accumulated goodwill impairment of $35.91 million, and the company is evaluating new tax legislation impacts.